Azitra (AZTR) Accounts Payables (2022 - 2026)
Azitra's (AZTR) quarterly Accounts Payables came in at $932217.0 in Q1 2026, up 66.79% YoY from $558924.0 in Q1 2025, and up 133.43% on a QoQ basis from $399356.0 in Q4 2025.
Azitra (AZTR) Accounts Payables (2022 - 2026) Analysis & Trends
Azitra (AZTR) has 5 years of Accounts Payables data on file, last reported at $932217.0 in Q1 2026.
- Quarterly Accounts Payables rose 66.79% year-over-year to $932217.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $932217.0 (up 66.79% YoY) and the FY2025 annual result came in at $399356.0, down 18.54% from the prior year.
- Accounts Payables advanced to $932217.0 in Q1 2026, from $399356.0 in the prior quarter.
- In the past five years, Accounts Payables ranged from a high of $996700.0 in Q2 2024 to a low of $364183.0 in Q2 2023.
- A 5-year average of $643642.7 and a median of $588460.0 in 2024 frame the typical range for Accounts Payables.
- The widest YoY moves for Accounts Payables: up 173.68% in 2024, down 45.36% in 2024.
- Tracing AZTR's Accounts Payables over 5 years: stood at $784687.0 in 2022, then gained by 14.35% to $897272.0 in 2023, then tumbled by 45.36% to $490255.0 in 2024, then fell by 18.54% to $399356.0 in 2025, then soared by 133.43% to $932217.0 in 2026.
- The last three Accounts Payables figures came in at $932217.0 (Q1 2026), $399356.0 (Q4 2025), and $718476.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Accounts Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.60 Bn | 130.75 Bn | 2.84 Bn | 429.50 Mn |
| 2 | Regeneron Pharmaceuticals | 85.93 Bn | 77.93 Bn | 3.93 Bn | 1.16 Bn |
| 3 | Argenx Se | 65.06 Bn | 59.88 Bn | 1.37 Bn | 1.52 Bn |
| 4 | Moderna | 56.22 Bn | 51.08 Bn | 52.00 Mn | 167.00 Mn |
| 5 | BeOne Medicines | 42.03 Bn | 36.93 Bn | 1.53 Bn | 470.30 Mn |
| 6 | Alnylam Pharmaceuticals | 31.65 Bn | 28.34 Bn | 992.69 Mn | 108.02 Mn |
| 7 | BioNTech SE | 27.70 Bn | 9.31 Bn | 668.28 Mn | 622.65 Mn |
| 8 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 428.93 Mn |
| 9 | Royalty Pharma | 27.31 Bn | 26.48 Bn | - | 35.57 Mn |
| 10 | Azitra | 2.55 Mn | 2.55 Mn | - | 497,985.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 497,985.00 |
| Mar 31, 2026 | 932,217.00 |
| Dec 31, 2025 | 399,356.00 |
| Sep 30, 2025 | 718,476.00 |
| Jun 30, 2025 | 635,842.00 |
| Mar 31, 2025 | 558,924.00 |
| Dec 31, 2024 | 490,255.00 |
| Sep 30, 2024 | 588,460.00 |
| Jun 30, 2024 | 996,700.00 |
| Mar 31, 2024 | 583,055.00 |
| Dec 31, 2023 | 897,272.00 |
| Sep 30, 2023 | 417,928.00 |
| Jun 30, 2023 | 364,183.00 |
| Dec 31, 2022 | 784,687.00 |